Skip to main content

Table 1 The performances of PCR-RDB genotyping cotesting and Cervista® cotesting for identifying CIN2+. (N = 24,819)

From: Cost-effectiveness and accuracy of cervical cancer screening with a high-risk HPV genotyping assay vs a nongenotyping assay in China: an observational cohort study

 

PCR-RDB cotesting

Cervista® cotesting

P-value

Arm 1 (n = 3272)

 Sensitivity

93.3% (87.7–98.9%)

80.6% (71.4–89.7%)

0.019

 Specificity

91.6% (90.7–92.6%)

93.4% (92.6–94.3%)

0.007

 PPV

20.8% (18.8–23.2%)

21.6% (19.9–23.9%)

0.873

 NPV

99.8% (99.8%–100.0%)

99.5% (99.3–99.7%)

0.031

 PLR

11.4 (9.8–12.7)

12.6 (10.3–14.6)

/

 NLR

0.07 (0.03–0.17)

0.21 (0.13–0.33)

/

 No. of cases identified at first round screening

70

58

/

 No. of cases identified at 1-year follow-up

5

14

/

 No. of cases identified at sequent follow-up

3

5

/

 No. of colposcopies to identified 1 case at first round

4.81

4.62

/

 Cost per 1000 screened women at first round screeninga

$ 52,292 (Â¥ 366,044)

$ 51,238 (Â¥ 358,666)

/

 Cost per 1000 screened women at 1-year follow-up

$ 5640 (Â¥ 39,480)

$ 6684 (Â¥ 46,788)

/

 Total cost per 1000 screened women per round

$ 57,932 (Â¥ 405,524)

$ 57,922 (Â¥ 405,454)

/

Cost per each identified CIN2+ women per round

$ 2527 (Â¥ 17,689)

$ 2632 (Â¥ 18,424)

/

Arm 2 (n = 11,638) vs. Arm 3 (n = 9909)b

 Sensitivity

93.2% (90.6–95.7)

80.7% (76.2–85.2)

< 0.001

 Specificity

93.0% (92.5–93.5)

95.7% (95.3–96.1)

< 0.001

 PPV

31.1% (28.4–33.7)

36.0% (32.3–39.7)

0.037

 NPV

99.8% (99.7–99.9)

99.4% (99.2–99.6)

< 0.001

 PLR

13.8 (12.4–14.3)

19.2 (16.7–20.8)

/

 NLR

0.07 (0.05–0.11)

0.20 (0.16–0.26)

/

 No. of cases identified at first round screening

355

234

/

 No. of cases identified at 1-year follow-up

26

56

/

 No. of cases identified at sequent follow-up

20

12

/

 No. of colposcopies to identified 1 case at first round screening

3.22

2.78

/

 Cost per 1000 screened women at first round screening

$ 52,053 (Â¥ 364,371)

$ 50,422 (Â¥ 352,954)

/

 Cost per 1000 screened women at 1-year follow-up

$ 4940 (Â¥ 34,580)

$ 6480 (Â¥ 45,360)

/

 Total cost per 1000 screened women per round

$ 56,993 (Â¥ 398,951)

$ 56,902 (Â¥ 398,314)

/

 Cost per each identified CIN2+ women per round

$ 1654 (Â¥ 11,578)

$ 1867 (Â¥ 13,069)

/

  1. PCR-RDB cotesting, primarily screens women with both cytology and PCR-RDB HR-HPV genotyping assays, and then refers those with cytology ASCUS and PCR-RDB HR-HPV positive/PCR-RDB HPV16 or HPV18 positive/cytology LSIL or worse to colposcopy; Cervista® cotesting, primarily screens women with both cytology and Cervista® HR-HPV assays, and then refers those with cytology ASC-US and HR-HPV positive/cytology LSIL or worse to colposcopy; Arm 1, composed of participants screened for cervical cancer using the Cervista® HR-HPV assay, PCR-RDB HPV genotyping assay and ThinPrep® Cytologic Test (TCT) simultaneously; Arm 2, composed of participants screened for cervical cancer using the PCR-RDB HR-HPV genotyping assay and the TCT; Arm 3, composed of participants screened using the Cervista® HR-HPV assay and the TCT
  2. CIN2+, cervical intraepithelial neoplasia grade 2 or worse; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio
  3. a Calculate only the cost of screening women for cervical cancer screening in hospitals
  4. b Compare Arm 2′s screening strategy with Arm 3′s screening strategy